353
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma

, , , &
Pages 329-339 | Received 09 Dec 2022, Accepted 19 Mar 2023, Published online: 05 Apr 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.